Brought to you by 
Lilly licenses Amylin's diabetes drug; deal ends with rights returned to Amylin
31 Jan 2012
Executive Summary
Eli Lilly will collaborate on further clinical development and commercialization of Amylin Pharmaceuticals' (treatments for diabetes and other metabolic diseases) AC2993 (exenatide), a Phase III candidate for Type II diabetes.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly licenses Amylin's diabetes drug; deal ends with rights returned to Amylin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice